drugset / Trial / NCT00005033
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
Treatment
Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have recurrent osteosarcoma.
Timeline
- Start
- 1999-12
- Primary completion
- —
- Completion
- 2004-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |